



## Ocular Therapeutix™ to Host Investor Day on April 6, 2016

March 28, 2016

BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 28, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Company will host an Investor Day on Wednesday, April 6, 2016 at 12:00 p.m. ET in New York, NY. The Company will be joined by several leading cataract, glaucoma, and retina specialists.

The live audio webcast and accompanying slide presentation can be accessed through the Calendar of Events section of the Company's website at [investors.ocutx.com](http://investors.ocutx.com). A replay of the webcast will be available on the Company's website for two weeks following the event.

### About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot, is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for inflammatory dry eye disease. An NDA for the post-operative ocular pain indication has been accepted for filing by the FDA with a PDUFA date of July 24, 2016. A third Phase 3 clinical trial is being conducted for post-operative ocular inflammation and pain. For glaucoma and ocular hypertension, a Phase 2b clinical trial has been completed with OTX-TP (sustained release travoprost) Intracanalicular Depot, and the first of two OTX-TP Phase 3 clinical trials is expected to be initiated in the third quarter of 2016. Ocular Therapeutix is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160328005634/en/>

Source: Ocular Therapeutix, Inc.

### Investors

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

[bsmith@ocutx.com](mailto:bsmith@ocutx.com)

or

Burns McClellan on behalf of Ocular Therapeutix

Steve Klass, 212-213-0006

[sklass@burnsmc.com](mailto:sklass@burnsmc.com)

or

### Media

Ocular Therapeutix, Inc.

Scott Corning

Vice President of Sales and Marketing

[scorning@ocutx.com](mailto:scorning@ocutx.com)